Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDeferred TaxesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Sanofi (SNY) over the last 12 years, with Q4 2025 value amounting to -$409.8 million.

  • Sanofi's Gains from Investment Securities fell 477.48% to -$409.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.4 billion, marking a year-over-year decrease of 2207.68%. This contributed to the annual value of -$117.5 million for FY2025, which is 7033.07% up from last year.
  • Per Sanofi's latest filing, its Gains from Investment Securities stood at -$409.8 million for Q4 2025, which was down 477.48% from -$391.1 million recorded in Q4 2024.
  • Sanofi's Gains from Investment Securities' 5-year high stood at -$391.1 million during Q4 2024, with a 5-year trough of -$409.8 million in Q4 2025.
  • Moreover, its 3-year median value for Gains from Investment Securities was -$391.6 million (2023), whereas its average is -$397.5 million.
  • In the last 5 years, Sanofi's Gains from Investment Securities rose by 13.69% in 2024 and then crashed by 477.48% in 2025.
  • Sanofi's Gains from Investment Securities (Quarter) stood at -$391.6 million in 2023, then grew by 0.14% to -$391.1 million in 2024, then decreased by 4.77% to -$409.8 million in 2025.
  • Its Gains from Investment Securities was -$409.8 million in Q4 2025, compared to -$391.1 million in Q4 2024 and -$391.6 million in Q4 2023.